#ExistRefRangeSet>
Reference Interval:
#ExistRefRange>By report
*ExistRefRange>
|
*ExistRefRangeSet>
#ExistInterpDataSet>
| Interpretive Data: |
#ExistInterpData>Background Information for Galactosemia, (GALT) 9 Mutations, Fetal: Characteristics: Affected infants present at 3-14 days old with poor feeding, vomiting, diarrhea, jaundice, lethargy progressing to coma, and abdominal distension with hepatomegaly usually followed by progressive liver failure. Patients with galactosemia are also at increased risk for E. coli or other Gram negative neonatal sepsis. Diagnosis is made by measuring GALT enzyme activity in red blood cells. Incidence: Approximately 1 in 30,000 to 60,000 for classic galactosemia in Caucasians; varies in other populations. Inheritance: Autosomal recessive. Penetrance: 100 percent for severe GALT mutations. Cause: Mutations in the GALT gene. Mutations Tested: Seven GALT gene mutations (Q188R, S135L, K285N, T138M, L195P, Y209C, and IVS2-2 A>G) and two variants (N314D and L218L). Clinical Sensitivity: Approaches 80 percent in Caucasians but reduced in other ethnic groups. Methodology: Polymerase chain reaction followed by single nucleotide extension (SNE) and capillary electrophoresis. Analytical Sensitivity: 99 percent for mutations listed. Limitations: GALT gene mutations, other than the 9 targeted, will not be detected. Rare diagnostic errors can occur due to primer site mutations.
For quality assurance purposes, ARUP Laboratories will provide a confirmation of the above result at no charge. Following delivery, please collect a cord blood sample from the infant in a lavender (EDTA) or yellow (ACD Solution A or B) top tube and transport 1mL cord blood at 2-8 °C. Please specify on the test request form that this is a confirmatory study to be performed at no charge. Please provide the mother's name for specimen identification purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.
Please refer to Statement C in the Compliance Statements section in the front of the Laboratory Test Directory.
*ExistInterpData>
|
*ExistInterpDataSet>
#ExistNote>
| Note: |
This test is offered to individuals with a known familial mutation(s).
|
*ExistNote>
#ExistCPT>
| CPT Code(s): |
83891 Isolation; 83898 Amplification; 83914 x9 Mutation identification; 83909 Capillary electrophoresis; 83912 Interpretation and report. FCC: 83900 Amplification multiplex (first two sequences); 83901 x14 Amplification; 83909 Capillary electrophoresis. If MCC MAT (0050608) is performed: 83891 Isolation; 83900 Amplification multiplex (first two sequences); 83901 x14 Amplification; 83909 Capillary electrophoresis; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncological or inherited disorders.
|
*ExistCPT>
|